Elanco Animal Health (NYSE:ELAN) Upgraded at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Elanco Animal Health (NYSE:ELAN – Free Report) from a buy rating to a strong-buy rating in a research report report published on Monday.

A number of other research analysts have also recently issued reports on ELAN. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. Barclays assumed coverage on Elanco Animal Health in a report on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price target for the company. Argus raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a report on Wednesday, November 19th. UBS Group boosted their price target on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Finally, JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $18.00 to $24.00 in a research note on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Elanco Animal Health has an average rating of “Moderate Buy” and an average target price of $23.78.

Read Our Latest Stock Analysis on ELAN

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $24.38 on Monday. The firm has a market capitalization of $12.11 billion, a P/E ratio of 406.32, a P/E/G ratio of 3.36 and a beta of 1.87. The firm’s 50-day moving average price is $22.62 and its 200-day moving average price is $19.87. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. Elanco Animal Health has a 1-year low of $8.02 and a 1-year high of $24.98.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The firm’s revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Equities research analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 22,000 shares of the business’s stock in a transaction on Thursday, December 11th. The stock was purchased at an average price of $21.75 per share, for a total transaction of $478,500.00. Following the completion of the transaction, the chief executive officer directly owned 167,000 shares of the company’s stock, valued at $3,632,250. This trade represents a 15.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Lawrence Erik Kurzius bought 10,000 shares of Elanco Animal Health stock in a transaction dated Friday, December 12th. The stock was acquired at an average price of $21.30 per share, with a total value of $213,000.00. Following the purchase, the director directly owned 131,773 shares of the company’s stock, valued at approximately $2,806,764.90. This represents a 8.21% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 43,450 shares of company stock worth $937,883 over the last 90 days. 0.89% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. SJS Investment Consulting Inc. boosted its holdings in shares of Elanco Animal Health by 2,563.5% in the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after acquiring an additional 1,333 shares during the period. Huntington National Bank boosted its stake in Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after purchasing an additional 1,087 shares during the period. Whittier Trust Co. of Nevada Inc. boosted its stake in Elanco Animal Health by 80.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after purchasing an additional 900 shares during the period. Farther Finance Advisors LLC grew its holdings in Elanco Animal Health by 79.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock valued at $43,000 after buying an additional 951 shares in the last quarter. Finally, Fifth Third Bancorp increased its position in shares of Elanco Animal Health by 3,018.3% during the third quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock valued at $58,000 after buying an additional 2,807 shares during the period. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Company Profile

(Get Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Featured Articles